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Objectives. This study sought to compare hormone replacement
therapy (HRT), simvastatin and their combination in the man-
agement of hypercholesterolemia in postmenopausal women with
coronary artery disease (CAD).
Background. Lipid-lowering therapy reduces mortality in hy-
percholesterolemic women with CAD. In postmenopausal women
HRT seems to increase survival, particularly those with ischemic
heart disease, and this is partly due to changes in lipid levels.
Methods. We studied 16 postmenopausal women with CAD and
fasting total cholesterol <200 mg/dl and low-density lipoprotein
(LDL) cholesterol <130 mg/dl. We compared HRT (0.625 mg of
conjugated estrogen and 2.5 mg of medroxyprogesterone acetate
daily) with simvastatin (20 mg daily) and their combination in a
randomized, crossover, placebo-controlled study. Each treatment
period was 8 weeks long with a 4-week washout interval between
treatments.
Results. Simvastatin, HRT and their combination significantly
reduced total and LDL cholesterol by 35%, 13%, and 33% and
45%, 20%, and 46%, respectively, compared to placebo (p <
0.001). However, simvastatin and the combination was superior to
HRT (p < 0.001), and none of our patients had total cholesterol
<180 mg/dl and LDL cholesterol <100 mg/dl on HRT alone.
High-density lipoprotein cholesterol was not significantly affected
by any of the active treatments, and triglycerides were lower
during simvastatin therapy compared to placebo (p < 0.01).
Apolipoprotein B was significantly reduced by simvastatin, alone
and combined with HRT, by 39% and 35%, respectively, compared
to placebo (p < 0.001). Alone and in combination with simvasta-
tin, HRT significantly increased apolipoprotein A-I by 11% and
12%, respectively, compared to placebo (p < 0.05) and decreased
lipoprotein (a) by 23% and 33%, respectively, compared to placebo
(p < 0.05), whereas simvastatin had no significant effect on either
of these parameters.
Conclusions. In hypercholesterolemic postmenopausal women
with CAD, HRT exerts beneficial effects on plasma lipids but the
levels currently recommended for secondary prevention are not
achieved. Hormone replacement therapy combined with simvasta-
tin is well tolerated and extremely effective, as the two therapies
seem to be additive.
(J Am Coll Cardiol 1998;32:1244–50)
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Hormone replacement therapy (HRT)—administration of es-
trogen and progestins—reduces the risk of coronary events in
postmenopausal women by up to 50% (1,2) and reduces
cardiovascular and total mortality (3,4); the greatest benefit
seems to occur in women with known coronary artery disease
(CAD) (5–7). These data, however, derive from observational
studies (8–11) and mainly concern estrogen administration
alone. Part of estrogen’s protective effect (25% to 50%) is due
to beneficial changes of plasma lipids (12). After menopause a
significant increase in total cholesterol, low-density lipopro-
teins (LDL) and lipoprotein (a) (Lp(a)) levels occurs whereas
high-density lipoproteins (HDL) falls (13–17). These unfavor-
able changes are reversed by estrogen replacement. Unop-
posed estrogen lowers total cholesterol, LDL and Lp(a) and
raises HDL levels in postmenopausal women with normal or
elevated baseline lipid levels (18–20); however, the addition of
progestins, obligatory in women with an intact uterus, may
attenuate or negate the beneficial effects of estrogen, and this
seems to vary with the degree of androgenic activity (21–23).
Treatment of hypercholesterolemia as primary prevention
has been shown to be effective for men (24) and evidence is
now also emerging for women (25). In addition, the majority of
prospective observational studies have reported a positive
association between CAD and total plasma cholesterol and an
inverse relation between CAD and HDL cholesterol in women
(26). Similarly, the 4 S (27), and the CARE (28), both
secondary prevention studies, have shown significant reduction
in coronary events and total mortality with a 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor
in patients of both sexes.
Women with CAD and hypercholesterolemia, even mild,
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should be treated aggressively with a lipid-lowering agent.
These women should also be considered for long-term HRT
unless there is a clear contraindication. Because HRT may
improve the lipid profile, it may be recommended as initial or
adjunct therapy in postmenopausal women with hypercholes-
terolemia and CAD.
This is the first randomized, crossover, placebo-controlled
study to compare simvastatin with HRT and their combination.
In a recent study, simvastatin was shown to be more effective in
decreasing total and LDL cholesterol compared with HRT and
equally effective in increasing HDL, but HRT uniquely low-
ered Lp(a) in hypercholesterolemic women (29). However, the
combination of the two therapies was not studied; there was no
placebo control in this study and the dose of HRT was higher
than that commonly prescribed. There is only one report of the
combined regimen being more effective than either treatment
alone, but unopposed estrogen was used in this study (30) and
this is a therapeutic option of limited value as it can only be
recommended in women with a previous hysterectomy. In
addition, both studies included women with and without CAD,
whereas we focused on women with CAD as they are more
likely to gain more from both HRT and lipid-lowering therapy.
Methods
Patients. Postmenopausal women, defined as having had
more than 12 months of amenorrhea, with documented CAD
were prospectively screened for participation in the study.
Patients receiving HRT or lipid-lowering agents entered an
initial 4-week-long washout period and subsequently followed
a National Cholesterol Education Program (NCEP) Step II
diet for 6 weeks. Patients with fasting serum total cholesterol
.200 mg/dl, LDL cholesterol .130 mg/dl and triglycerides
,500 mg/dl after 6 weeks of NCEP Step II diet were included
in the study. Women with a history of breast cancer or
endometrial cancer or a strong family history of estrogen-
related cancer were excluded from the study as were those with
previous thromboembolic disease and liver disorders. All
patients had a normal mammogram and a normal cervical
smear within the last year as well as normal liver and thyroid
function tests. All our patients had angiographically proved
significant CAD with at least one .80% diameter stenosis of
an epicardial vessel and positive exercise test, and were
clinically stable. Patients with myocardial infarction or unsta-
ble angina within a period of 3 months before enrollment, with
severe uncontrolled hypertension, previous stroke or on anti-
coagulants were excluded from the study.
The study protocol was approved by the institutional com-
mittee on human research and a written informed consent
form was obtained from all patients.
Protocol. This was a randomized, placebo-controlled,
crossover study. All patients were randomly assigned to pla-
cebo, continuous combined HRT with 0.625 mg of conjugated
estrogens (Premarin, Wyeth Hellas, Athens, Greece) and
2.5 mg of medroxyprogesterone acetate (Provera, Upjohn,
Athens, Greece), once daily, simvastatin 20 mg (Zocor, MSD,
Athens, Greece), once daily, and the combination of HRT and
simvastatin, in all 24 possible orders (Latin square). Each
treatment period was 8-weeks long and the washout period
between them was a 4-week interval. We had to enroll 24
patients according to the study design but we terminated the
study early, due to significant results, at a prescheduled interim
analysis when 16 women had completed the protocol.
All our patients remained on the same antianginal–
antihypertensive regimen throughout the study period and the
same occurred with the thyroid supplements. Likewise, the
patients were advised to continue the NCEP diet during all
treatment arms.
Blood was sampled, after a 12-h fast, at the end of each of
the four treatment periods.
Measurement of lipid and lipoproteins. Serum total cho-
lesterol, triglycerides and HDL were measured by photometry
(Cobas Integra Analyzer, Roche, Swiss), with MgCL2 and
dextran sulfate precipitation of the plasma for the HDL
measurement. The LDL cholesterol was calculated by the
Friedewald formula because the triglyceride level was less than
400 mg/dl in all our patients. Apolipoprotein B, apolipoprotein
A-I and Lp(a) were measured by nephelometry (Nephelome-
ter Analyzer 100, Behring, Germany).
Statistical analysis. Results are expressed as mean value 6
SD. Lipoprotein(a) was not normally distributed and therefore
median values are also presented. The effect of each treat-
ment—simvastatin, HRT and the combination therapy—
compared to placebo is examined with the Scheffe test. The
effect of each drug, alone and combined, and the interaction
term between simvastatin and HRT is analyzed with repeated
measures two way analysis of variance. A p value ,0.05 was
considered significant. We used the statistical package Statis-
tica, Version 4.3 F (1993 edition) by StatSoft Inc (Tulsa,
Oklahoma).
Results
We studied 18 women, 66 6 4 years of age (range 58 to 72).
Fifteen patients had already undergone revascularization pro-
cedures, nine had percutaneous transluminal coronary angio-
plasty, five had coronary artery bypass grafting and one had
both; the remaining three patients were on medical therapy.
Two of our patients did not complete the protocol; one did
Abbreviations and Acronyms
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CARE 5 Cholesterol and Recurrent Events Trial
4 S 5 Scandinavian Simvastatin Survival Study
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not take the combination therapy (HRT and simvastatin)
because she developed severe breast tenderness while on HRT
alone and the other refused to take the placebo as she
presented with angioplasty restenosis during the course of the
study. Both these patients were excluded from final analysis.
All treatments were well tolerated. Ten patients reported
mastalgia while on HRT but only one of the 17 women who
had an intact uterus suffered vaginal bleeding immediately
after cessation of HRT, both alone and in combination with
simvastatin.
Baseline values of lipid and lipoproteins are shown in Table
1 and the effects of all four treatments are summarized in
Table 2.
All three active treatments—simvastatin, HRT, and their
combination—significantly reduced total cholesterol levels
compared to placebo values by 35%, 13% and 33%, respec-
tively (p , 0.001). However, simvastatin and its combination
with HRT was more effective than HRT alone (p , 0.001),
whereas the combination was not better than simvastatin
alone. Similarly, LDL cholesterol was significantly reduced by
45%, 20% and 46%, respectively, compared to placebo (p ,
0.001), and again simvastatin alone and in combination, proved
superior to HRT (p , 0.001), with the combination therapy
not different from simvastatin (Fig. 1). Apolipoprotein B,
however, was significantly reduced by simvastatin both alone
and in combination by 39% and 35%, respectively, compared
to placebo (p , 0.001), whereas HRT alone had no significant
effect; there was no difference between simvastatin and the
combination regimen in apolipoprotein B levels (Fig. 2). When
the overall effect of each drug, simvastatin and HRT, alone and
in combination, was examined, both were found to have
significant effect on total and LDL cholesterol (p , 0.001 and
p 5 0.015 for total cholesterol and p , 0.001 and p 5 0.002 for
LDL cholesterol, respectively) and the interaction term be-
tween the two drugs was also significant (p , 0.001 for both
total and LDL cholesterol). Likewise, the interaction term
between simvastatin and HRT for apolipoprotein B was sig-
nificant (p 5 0.014), but only the overall effect of simvastatin
on this parameter was of statistical significance (p , 0.001).
None of the active treatments had any significant effect on
HDL cholesterol levels compared to placebo (Fig. 1), the
overall effect of each drug and their interaction term being also
nonsignificant. However, apolipoprotein A-I was significantly
increased by HRT alone and in combination with simvastatin
by 11% and 12%, respectively, compared to placebo (p 5 0.038
and p 5 0.028); the combination was not superior to HRT
alone (Fig. 2). The overall effect of HRT, alone and combined
with apolipoprotein A-I, was significant (p 5 0.003), whereas
the simvastatin effect and their interaction term were not.
Triglyceride levels were decreased by 33% by simvastatin
compared to placebo (p 5 0.009) (Fig. 1) and the overall effect
of simvastatin, alone and in combination, on triglycerides was
significant (p 5 0.001), but the HRT effect and their interac-
tion term were not.
Only HRT, alone and combined with simvastatin, signifi-
cantly reduced Lp(a) levels by 23% and 33% compared to
placebo (p 5 0.019 and p 5 0.001, respectively), with simva-
statin having no effect. The combination of HRT and simva-
statin were not more effective in Lp(a) reduction than HRT
alone (Fig. 2). The overall effect of HRT, alone and combined,
Table 1. Baseline Values of Serum Lipids and Lipoprotein Levels of
16 Postmenopausal, Hypercholesterolemic Women With Coronary
Artery Disease
Total cholesterol 269 6 41
(206–332)
LDL 194 6 38
(133–267)
HDL 49 6 11
(35–69)
Triglycerides 127 6 36
(77–192)
Apo B 164 6 24
(116–199)
Apo A-I 164 6 26
(126–213)
Lp(a) 37 6 27 [29]
(12–119)
Values are expressed as mean 6 SD (range). For Lp(a), median values are
also presented in brackets. Results are expressed in milligrams per deciliters.
Apo A-I, Apo B 5 apolipoproteins A-I and B; HDL 5 high-density lipoprotein;
LDL 5 low-density lipoprotein; Lp(a) 5 lipoprotein (a).
Table 2. Effects of Placebo, Simvastatin, HRT and the Combination of Simvastatin and HRT on Serum Lipids and Lipoprotein Levels of 16
Postmenopausal, Hypercholesterolemic Women With Coronary Artery Disease
Total
Cholesterol LDL HDL Triglycerides Apo B Apo A-I Lp(a)
Placebo 272 6 33 194 6 30 48 6 11 151 6 64 172 6 23 170 6 25 30 6 21 [24]
(214–321) (146–240) (32–77) (72–277) (135–229) (126–210) (8–24)
Simvastatin 178 6 29** 106 6 26** 51 6 10 101 6 25** 105 6 21** 177 6 21 31 6 22 [23]
(120–242) (61–168) (36–72) (70–150) (70–151) (143–224) (8–96)
HRT 237 6 31** 155 6 29** 52 6 11 149 6 36 160 6 26 189 6 21* 23 6 16* [16]
(185–286) (107–209) (34–73) (108–253) (114–200) (161–233) (8–66)
Simvastatin/HRT 182 6 24** 105 6 20** 50 6 10 130 6 42 112 6 22** 190 6 26* 20 6 16** [16]
(146–226) (73–149) (36–73) (62–206) (76–15) (156–258) (48–74)
Values are expressed as mean 6 SD (range). For Lp(a), median values are also presented in brackets. Results are expressed in milligrams per deciliter. *p , 0.05;
**p , 0.01. HRT 5 hormone replacement therapy; other abbreviations as in Table 1.
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on Lp(a) was very significant (p , 0.001); however, the
simvastatin effect and their interaction term were not.
Two thirds of the patients had total cholesterol ,180 mg/dl
and LDL ,100 mg/dl on both simvastatin and the combined
therapy whereas none achieved these targets on HRT alone.
All patients had triglycerides ,200 mg/dl and HDL .35 mg/dl
on simvastatin and the combination therapy, and all but one on
HRT alone. Lipoprotein (a) ,30 mg/dl was reached in 11, 12
and 15 patients with simvastatin, HRT and the combined
therapy, respectively.
Discussion
This study compared the effects of HRT (conjugated estro-
gen plus medroxyprogesterone acetate), simvastatin and their
Figure 1. Total cholesterol, LDL cholesterol,
HDL cholesterol and triglyceride levels
(mean 6 SD) with placebo, simvastatin, HRT
and the combination of simvastatin and HRT.
**p , 0.01 compared to placebo.
Figure 2. Apolipoprotein B, apolipoprotein
A-I and Lp(a) levels (mean 6 SD) with
placebo, simvastatin, HRT and the combina-
tion of simvastatin and HRT. *p , 0.05 and
**p , 0.01 compared to placebo.
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combination with placebo in postmenopausal women with
hypercholesterolemia and CAD. We found that all three
treatments significantly reduced total and LDL cholesterol
compared to placebo. Simvastatin, however, both alone and in
combination with HRT, was more effective than HRT alone. In
addition, simvastatin, alone and combined, significantly de-
creased apolipoprotein B levels, whereas HRT failed to do so.
Conversely, HRT, alone and combined with simvastatin, sig-
nificantly increased apolipoprotein A-I and decreased Lp(a)
levels compared to placebo, whereas simvastatin had no sig-
nificant effect on either of these parameters. The HDL cho-
lesterol level did not change significantly with any of the
treatments, and triglycerides were lower in the simvastatin
group compared to placebo.
Effects on lipid levels. Estrogen lowers LDL cholesterol by
upregulating LDL receptors in the liver and enhancing LDL
catabolism (18). We indeed found a significant decrease in
total and LDL cholesterol levels with HRT, but simvastatin
proved to be more powerful in total and LDL cholesterol
reduction; the combination of the two treatments was not
superior than simvastatin alone. None of our women had
a total cholesterol ,180 mg/dl and an LDL cholesterol
,100 mg/dl on HRT alone. Our results are similar to previous
studies (29,30). In the study by Darling et al. (29), even a lower
dose of simvastatin (10 mg) was more effective than HRT in
total and LDL cholesterol reduction. Likewise in the study by
Davidson et al. (30), pravastatin was better than conjugated
estrogen in total and LDL cholesterol reduction, and the
combination of conjugated estrogen with pravastatin was
shown to further decrease only the LDL/HDL ratio compared
to pravastatin alone. The LDL subfractions were not mea-
sured.
Simvastatin and HRT increased HDL by 6% and 8%,
respectively, but this did not reach statistical significance
compared to placebo; the HDL subfractions were not evalu-
ated. In the study by Darling et al. (29), both simvastatin and
HRT increased HDL by 7%, but the significance of this is not
reported. Our results are also comparable with Denke (31),
who used the same HRT regimen and found a 6% increase in
HDL levels after 3 months of treatment. Estrogen use is
associated with elevations in HDL by up to 25% (9,18,19,30),
and HDL seems to be the best predictor of coronary heart
disease risk in women (32,33). Estrogen’s induced rise in HDL,
however, is blunted by the addition of progestins (21–23,34). In
addition, there are reports of combined estrogen and progestin
administration where HDL levels are unchanged (14,35,36) or
have even decreased (37,38).
Hormone replacement therapy, alone and combined with
simvastatin, did not increase triglycerides levels. Unopposed
estrogen usually but not invariably (39,40) increases triglycer-
ides levels, possibly in a dose-dependent manner (18), and
progestins seem to attenuate this effect (22). The Framingham
Offspring Study (34), however, showed no change in triglycer-
ide levels with the combination therapy and neither did other
studies assessing oral continuous combined therapy (35,38).
Effects on lipoprotein levels. We found a significant de-
crease in Lp(a) with HRT, both alone and combined with
simvastatin. This is in agreement with previous studies
(9,20,29,35,36,41). Lipoprotein(a) is a lipoprotein with struc-
tural features of LDL and plasminogen and therefore is
believed to be both proatherogenic and antithrombolytic.
Additionally, Lp(a) concentrations appear to be relatively
resistant to environmental changes, and at present there is no
effective therapy available to lower high Lp(a) levels. Epide-
miologic studies have demonstrated a significant correlation
between increased levels of Lp(a) and the incidence of coro-
nary disease (42). Whether Lp(a) is an independent risk factor,
however, remains controversial (43), and its importance seems
to decline with age, particularly in women (44).
Hormone replacement therapy, alone and in combination
with simvastatin, significantly increased apolipoprotein A-I
levels; similarly, previous studies (14,18,19,34) have reported
that estrogen use is associated with elevations in apolipopro-
tein A-I by 13% to 22%, due to increased synthesis, and this
effect is not abolished or attenuated by the addition of
progesterone (19,34) in contrast to HDL levels that are
significantly affected by progestins (34). The elevation of
apolipoprotein A-I in response to HRT would be expected to
favorably affect the atherogenic risk.
Apolipoprotein B was significantly reduced by simvastatin,
alone and in combination, whereas HRT caused only a mild
reduction in apolipoprotein B levels. Likewise, the Framing-
ham Offspring study (34) reported a nonsignificant decrease in
apolipoprotein B values in users of combined HRT versus
nonusers; other studies, however, found a more pronounced
decrease in apolipoprotein B levels with HRT (35,41).
Secondary prevention with statins and HRT. Lipid-
lowering therapy appears to be beneficial in women with
known CAD. Although data are limited, there is substantial
evidence that there is a .50% reduction in CAD mortality
among treated women (45). In both the 4 S (27) and the CARE
(28) studies, HMG-CoA reductase inhibitor therapy was asso-
ciated with equivalent or even greater risk reduction in major
coronary events in women compared to men. Although the
NCEP currently recommends an LDL ,100 mg/dl for both
men and women with CAD (46), a recent report claims that
more than 90% of women in the United States are under-
treated (47).
There is increasing epidemiologic evidence that postmeno-
pausal HRT reduces total and cardiovascular morbidity (1,2)
and mortality (3,4) with multiple mechanisms (48,49). A very
recent analysis, using a Markov model, suggests that HRT may
increase life expectancy for almost all postmenopausal women
by 3 years (50). However, there is an increased relative risk of
breast cancer in long-term users of HRT (51) and possibly of
deep vein thrombosis and pulmonary embolism (52–54). Re-
cently, selective estrogen-specific modulators have been shown
to decrease total and LDL cholesterol and increase bone
mineral density without inducing endometrial hyperplasia (55).
Limitations. The sample size is small and although our
results are significant, larger cohorts need to be studied. The
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length of treatment may have been inadequate, at least for
HRT; this may explain our negative HDL results as well as the
discordance between HDL and apo A-I effects.
Conclusions. We have shown that conjugated estrogen
combined continuously with medroxyprogesterone acetate in
conventional doses, although significantly decreases total and
LDL cholesterol compared to placebo, fails to achieve the
levels currently recommended for secondary prevention. It
seems, therefore, that only a few women with mild hypercho-
lesterolemia may adequately be treated with HRT as a single
lipid-lowering therapy, an option that should not be omitted
because it is cost effective and has other noncardiovascular
benefits (56–58). Hormone replacement therapy significantly
increases apolipoprotein A-I levels and decreases Lp(a) com-
pared to placebo, and this is a unique effect that an HMG-CoA
reductase inhibitor does not exert. The combination of HRT
and simvastatin is well tolerated, is without any serious adverse
reactions, at least during short-term administration, and is
extremely effective in lowering LDL and Lp(a) and raising
apolipoprotein A-I levels. We therefore conclude that post-
menopausal women with hypercholesterolemia and CAD
should, in a stepwise fashion, be treated with diet, followed by
HRT, if not contraindicated, and if inadequate as mono-
therapy, followed by a statin alone or in combination with
HRT.
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